T cells engineered with synthetic chimeric receptors (CAR T) have achieved impressive success in hematologic cancers, raising expectations that CAR T cells can be applied to treat solid tumors. Data from animal models and from initial studies in patients have identified numerous obstacles that must be overcome to achieve the success observed in hematologic cancers.  Advances in genetic engineering, synthetic biology, T cell biology, and improved tumor models that recapitulate the obstacles in human tumors have identified strategies that can be evaluated in the clinic.

Stanley RIDDELL Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA
Dr. Riddell is a Member at the Fred Hutchinson Cancer Research Center, Professor, Department of Medicine at the University of Washington, and Distinguished Affiliate Professor at the Technical University of Munich. He is the Virginia Hobbs Charitable Trust Research Professor of the American Cancer Society. His work has focused on the development and clinical translation of T cell therapy for cancer.